MSD’s Cancidas will retain premium pricing for up to 5 yrs

By Lee, Tak-Sun | translator Kang, Shin-Kook

24.05.08 05:52:50

가나다라 0

1-year first-in-class premium + 2-year less than 3 year premium + 2-year DREC0deliberated premium

Will be able to retain a price at the 70% level of the highest price after generic entry...until May next year

MSD's antifungal injection Cancidas’s premium pricing will be maintained for 5 years after generic entry. Originally, the price should have been adjusted to 53.55% of the highest price, but for various reasons, its price has remained at the level of 70% of the highest price.

According to the industry sources on the 6th, Cancidas’s drug pricing premium was supposed to end on the 1st of this month, but the pricing premium was extended for another year according to the opinion of the Drug Reimbursement Evaluation Committee.

As a result, the price of Cancidas 50mg will remain at KRW 215,977 and Cancidas 70mg at KRW 275,989.

Sam Chung Dang Pharm’s Casfun Inj, the only gener

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)